Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

FGFR

The fibroblast growth factor receptors (FGFR) are, as their name implies, receptors that bind to members of the fibroblast growth factor (FGF) family of proteins. Some of these receptors are involved in pathological conditions. For example, a point mutation in FGFR3 can lead to achondroplasia.

  • Lenvatinib
    T0520417716-92-8
    Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4 5.2 nM). Lenvatinib has strong anti-tumor activity.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Nintedanib
    T1777656247-17-5
    Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34 13 13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69 37 108 nM), PDGFRα, and PDGFRβ (IC50=59 65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
    • $38
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Erdafitinib
    T37261346242-81-6
    Erdafitinib (JNJ-42756493), a quinoxaline derivative, targets FGFR1 2 3 4.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Heparan Sulfate
    T193559050-30-0
    Heparan sulfate is a natural product, a linear polysaccharide. Heparan sulfate occurs as a proteoglycan (HSPG) that is tightly attached to cell surface or extracellular matrix proteins.
    • $44
    In Stock
    Size
    QTY
  • AZD4547
    T19481035270-39-3
    AZD4547 is an FGFR family inhibitor. AZD4547 selectively inhibits FGFR1 phosphorylation and suppresses cancer cell proliferation through inhibition of FGFR1 signaling, and is able to act on FGFR1 (IC50:0.2 nM), FGFR2 (IC50:2.5 nM), FGFR3 (IC50:1.8 nM) and FGFR4 (IC50:165 nM). IC50:165 nM).[2]
    • $33
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Pemigatinib
    T124011513857-77-6
    Pemigatinib (INCB054828) is an orally active, selective inhibitor of FGFR, with IC50 values of 0.4 nM for FGFR1, 0.5 nM for FGFR2, 1.2 nM for FGFR3, and 30 nM for FGFR4.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
    TargetMol | Citations Cited
  • Sulfatinib
    T40751308672-74-3
    Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1 2 3, FGFR1 and CSF1R with IC 50 s ranging from 1 to 24 nM.
    • $39
    In Stock
    Size
    QTY
  • Nintedanib esylate
    T5001656247-18-6
    Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1 2 3, FGFR1 2 3, and PDGFRα β.
    • $36
    In Stock
    Size
    QTY
  • Lenvatinib mesylate
    T8541857890-39-2
    Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Dovitinib
    T6289405169-16-6
    Dovitinib is an orally active, multi-targeted tyrosine kinase (RTK) inhibitor with anti-tumor effects.
    • $39
    In Stock
    Size
    QTY
  • Ponatinib
    T2372943319-70-8
    Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor with IC50 values of 0.37 nM (Abl), 1.1 nM (PDGFRα), 1.5 nM (VEGFR2), 2.2 nM (FGFR1), and 5.4 nM (Src).
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Aprutumab
    T766721634620-63-5
    Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
    • $572
    In Stock
    Size
    QTY
  • Infigratinib
    T1975872511-34-7
    Infigratinib (NVP-BGJ398) (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Formononetin
    T0724485-72-3
    Formononetin (Flavosil) is an O-methylated isoflavone and a phytoestrogen from the root of Astragalus membranaceus.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SM27
    T248046266-54-2In house
    SM27 is a fibroblast growth factor 2 (FGF2) inhibitor with anti-angiogenic activity and can be used to study tumours.
    • $195
    In Stock
    Size
    QTY
  • Pazopanib
    T0097L444731-52-6
    Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms (IC50=10 30 47 84 74 140 146 nM). Pazopanib has antitumor activity.
    • $42
    In Stock
    Size
    QTY
  • Dovitinib lactate hydrate
    T6479915769-50-5
    Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3 c-Kit) with IC50 of 1 nM 2 nM, also potent to class IV (FGFR1 3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.
    • $50
    In Stock
    Size
    QTY
  • PF 477736
    T6028952021-60-2
    PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
    • $45
    In Stock
    Size
    QTY
  • LY2874455
    T23611254473-64-7
    LY2874455 has been used in trials studying the treatment of Advanced Cancer.
    • $58
    In Stock
    Size
    QTY
  • Dovitinib lactate
    T7104692737-80-7
    Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM).
    • $47
    In Stock
    Size
    QTY
  • EOC317
    T4318939805-30-8
    EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50 values of 6 nM, 2 nM, and 4 nM for FGFR1, VEGFR2, and Tie-2, respectively.
    • $93
    In Stock
    Size
    QTY
  • PD173074
    T2642219580-11-7
    PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR and c-Src.
    • $36
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Futibatinib
    T50441448169-71-8
    Futibatinib (TAS-120) is an orally active, potent, selective, highly bioavailable, and irreversible FGFR inhibitor with IC50 values ​​of 3.9, 1.3, 1.6, and 8.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. [2]
    • $53
    In Stock
    Size
    QTY
  • FGFR2-IN-3
    T601852549174-42-5
    FGFR2-IN-3 is an orally active selective FGFR2 inhibitor[1].
    • $87
    In Stock
    Size
    QTY
  • Derazantinib
    TQ02281234356-69-4
    Derazantinib (ARQ-087) is a potent, ATP-competitive, orally active tyrosine kinase inhibitor with IC50 values ​​of 4.5 1.8 4.35 3.4 nM for chondrocyte FGFR1 FGFR2 FGFR3 FGFR4, respectively.
    • $52
    In Stock
    Size
    QTY
  • PHA-665752
    T6128477575-56-7
    PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
    • $59
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Ferulic Acid
    T22151135-24-6
    Ferulic Acid (Coniferic acid) is a highly abundant phenolic phytochemical and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.It can be absorbed by the small intestine and excreted through the urine.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Danusertib
    T2094827318-97-8
    Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
    • $54
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
    TargetMol | Citations Cited
  • Tyrosine kinase-IN-1
    T5466705946-27-6
    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor that acts on KDR, Flt-1, FGFR1, and PDGFRα with IC50 values of 4 nM, 20 nM, 4 nM, and 2 nM, respectively.
    • $35
    In Stock
    Size
    QTY
  • Amlexanox
    T163968302-57-8
    Amlexanox (AA673) is an anti-aphthous ulcer drug. Amlexanox inhibits the synthesis and release of inflammatory mediators, including leukotrienes and histamine, from mast cells, neutrophils, and mononuclear cells. Amlexanox also acts as a leukotriene D4 antagonist and a phosphodiesterase inhibitor. Amlexanox decreases the time ulcers take to heal as well as the pain associated with the ulcers.
    • $32
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PD-089828
    T8976179343-17-0
    PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 µM)
    • $31
    In Stock
    Size
    QTY
  • ODM-203
    T76111430723-35-5
    ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
    • $36
    In Stock
    Size
    QTY
  • Gandotinib
    T26381229236-86-5
    LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JAK1 and JAK3.
    • $47
    In Stock
    Size
    QTY
  • Fisogatinib
    T34561707289-21-1
    Fisogatinib (BLU-554) is a highly potent, selective and orally active FGFR4 inhibitor with an IC50 value of 5 nM and significant anti-tumor activity in hepatocellular carcinoma models dependent on FGFR4 signaling.
    • $51
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Roblitinib
    T42351708971-55-4
    Roblitinib (FGF-401) is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4) with potential antineoplastic activity. Upon administration, Roblitinib binds to and inhibits FGFR4, leading to the inhibition of tumor cell proliferation in FGFR4-overexpressing cells. It is a receptor tyrosine kinase upregulated in certain tumor cells and involved in proliferation, differentiation, angiogenesis, and survival.
    • $53
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
    TargetMol | Citations Cited
  • Ponatinib Hydrochloride
    T2372L1114544-31-8
    Ponatinib Hydrochloride (AP-24534 Hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
    • $43
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • H3B-6527
    T77381702259-66-2
    H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma, with antineoplastic activity.
    • $64
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Masitinib
    T2609790299-79-5
    Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
    • $31
    In Stock
    Size
    QTY
  • PRN1371
    TQ00151802929-43-6
    PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6 1.3 4.1 19.3 8.1 nM for FGFR1 2 3 4 and CSF1R).
    • $74
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Mubritinib
    T6124366017-09-6
    Mubritinib (TAK-165) (TAK-165) is a potent inhibitor of HER2 ErbB2 with IC50 of 6 nM.
    • $208
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Rogaratinib
    T167811443530-05-9
    Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity.
    • $149
    In Stock
    Size
    QTY
  • SU 5402
    T6996215543-92-3
    SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 values of 20 nM for VEGFR2, 30 nM for FGFR1, and 510 nM for PDGF-Rβ.
    • $59
    In Stock
    Size
    QTY
  • SU11274
    T6154658084-23-2
    SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
    • $39
    In Stock
    Size
    QTY
  • FGFR1/DDR2 inhibitor 1
    T112792308497-58-5
    FGFR1 DDR2 inhibitor 1 is an inhibitor of discoidin domain receptor 2 (DDR2) and fibroblast growth factor receptor 1 (FGFR1), with IC50 values of 31.1 nM, 108.4 nM, and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.
    • $93
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • ZM323881 hydrochloride
    T1991193000-39-4In house
    ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.
    • $66
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • 2,5-Dihydroxybenzoic acid
    T2857490-79-9
    2,5-Dihydroxybenzoic acid (Gentisic acid) is an active metabolite of salicylic acid degradation with a broad spectrum of biological activity, such as anti-inflammatory, antirheumatic and antioxidant properties.
    • $41
    In Stock
    Size
    QTY
  • S49076
    T32741265965-22-7
    S49076 is a novel and potent inhibitor of MET, AXL MER, and FGFR1 2 3, effectively blocking cellular phosphorylation of MET, AXL, and FGFRs.
    • $39
    In Stock
    Size
    QTY
  • TAK-632
    T18861228591-30-7
    TAK-632, a potent pan-Raf inhibitor (GenScript, 2020), is characterized by its molecular weight [M] for [C 22 H 19 FN 2 O 2] of 362.4 by LC-MS, with a purity of 99% (HPLC). The compound exhibits white to off-white solid form and has a melting point [M] ranging from 178°C to 182°C (GenScript, 2020). Its solubility profile includes DMSO, in which it is soluble to 100mM (GenScript, 2020).
    • $35
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Lucitanib
    T151851058137-23-7
    Lucitanib (E-3810) is a novel and potent inhibitor of VEGFR and FGFR, selectively targeting VEGFR1, VEGFR2, VEGFR3, FGFR1, and FGFR2 with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • KI8751
    T2446228559-41-9
    KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale